SCHEDULE 13G: BlackRock Inc. Reports 6.2% Ownership in Xenon Pharmaceuticals Inc.

BlackRock, Inc. files Schedule 13G, disclosing beneficial ownership of 6.2% of Xenon Pharmaceuticals Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. has filed a Schedule 13G with the SEC regarding its ownership in Xenon Pharmaceuticals Inc.
• As of June 30, 2025, BlackRock beneficially owns 4,757,709 shares of Xenon Pharmaceuticals Inc.'s common stock.
• This represents 6.2% of the outstanding shares of Xenon Pharmaceuticals Inc.'s common stock.
• BlackRock has sole voting power over 4,636,731 shares and sole dispositive power over 4,757,709 shares.
• Various persons have the right to receive dividends or proceeds from the sale of Xenon Pharmaceuticals Inc. common stock, but no single person's interest exceeds 5% of the outstanding shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard ownership disclosure.

Positives

• BlackRock's substantial investment indicates confidence in Xenon Pharmaceuticals Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure required by the SEC for institutional investors holding more than 5% of a publicly traded company's stock. It provides transparency regarding ownership and potential influence.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership.
• Company: Awareness of a significant investor's position.

Key Dates

Keywords

Schedule 13G, BlackRock, Xenon Pharmaceuticals, Beneficial Ownership, SEC Filing, Common Stock, Investment